Phase Ib Gene Editing Trials Market Revenue and Forecast by 2033

23 Jul 2025

Share :

Table of Content

1. Phase Ib Gene Editing Trials Market Revenue and Trends 2025 to 2033 2. What are the Key Factors Boosting the Growth of the Phase Ib Gene Editing Trials Market? 3. Segment Insights 4. Regional Insights 5. Phase Ib Gene Editing Trials Market Coverage 6. Phase Ib Gene Editing Trials Market Key Players

Phase Ib Gene Editing Trials Market Revenue and Trends 2025 to 2033

The phase Ib gene editing trials market focuses on early clinical trials assessing gene editing therapies for safety and initial efficacy. As next-generation tools like CRISPR advance, these trials are crucial in translating lab breakthroughs into human treatments. The growth of the market is driven by the rising development of novel one-time therapeutic candidates, surging investments in clinical trials, and regulatory pathways for gene therapies.

What are the Key Factors Boosting the Growth of the Phase Ib Gene Editing Trials Market?

The phase Ib gene editing trials market is experiencing rapid growth, driven by the increasing prevalence of genetic and rare diseases, which fuels the demand for novel, gene-targeted treatments. Advancements in the accuracy, safety, and effectiveness of gene editing technologies like CRISPR, ZFN, and TALENs in early-stage clinical trials are also accelerating progress. A notable increase in biopharmaceutical R&D investment, particularly in early-phase clinical trials, has spurred the development of therapies in early clinical stages. Supportive regulatory developments and emerging fast-track approval frameworks are also encouraging companies to engage in phase Ib studies. The growing interest in personalized medicine and targeted treatments further boosts the growth of the market.

Segment Insights

• By gene editing platform, the CRISPR/Cas systems segment registered dominance in the market for phase Ib gene editing trials because of their accuracy, effectiveness, and reproducibility, making them the leading platform for genome editing across various fields. These systems precisely target or modify DNA sequences, offering extraordinary control over the genetic makeup of organisms.
• By therapy type, the in vivo gene editing therapies segment held the largest share of the market in 2024. The dominance of these therapies stems from their proven effectiveness, higher activity, and longer duration of potential therapeutic effects.
• By disease area, the oncology segment dominated the market in 2024 due to the increased demand for targeted therapies, in which gene editing plays a crucial role. Increasing oncology research further supports segmental growth.
• By delivery method, the electroporation segment led the market with a major revenue share in 2024. This is mainly due to its highest levels of transfection compared to other methods and its safety with RNA or DNA delivery.
• By trial sponsor type, the biotech & pharma companies segment led the market in 2024 due to their increased participation in R&D and expanding pipeline for novel gene therapies.

Regional Insights

North America registered dominance in the phase Ib gene editing trials market by holding the largest share in 2024. This is mainly due to its robust R&D infrastructure and favorable regulatory pathways for early-phase trials. The increasing prevalence of cancer and the greater need for gene-specific targeted therapies further support regional market growth.

Asia Pacific is emerging as the fastest-growing region in the market. Countries like China, Japan, India, and South Korea are rapidly advancing their clinical trial infrastructure, backed by government support for the biotech industry. There is a high demand for gene therapies, driven by the increasing prevalence of genetic disorders, which contributes to market growth.

Phase Ib Gene Editing Trials Market Coverage

Recent Development

• In July 2025, Solid Biosciences plans to launch a phase 1b clinical trial in the final quarter of this year. SGT-501 is intended to address CPVT by providing a full-length, codon-optimized copy of the cardiac calsequestrin (CASQ2) gene to the muscle cells of the heart. (Source: https://www.cgtlive.com)

Phase Ib Gene Editing Trials Market Key Players

• Allogene Therapeutics
• Beam Therapeutics
• Caribou Biosciences
• Cellectis
• CRISPR Therapeutics
• EdiGene
• Editas Medicine
• Excision BioTherapeutics
• Graphite Bio
• iECURE
• Intellia Therapeutics
• LogicBio Therapeutics
• Metagenomi
• Poseida Therapeutics
• Precision BioSciences
• Regenxbio
• Sana Biotechnology
• Sangamo Therapeutics
• Tessera Therapeutics
• Verve Therapeutics

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6443

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344